The headline result beat a low market bar. Vaalco reported diluted EPS of $0.39 versus a published consensus of roughly $0.05, a substantial accounting beat. The quarter also benefited from unusually strong lifting timing and commodity pricing rather than a clean underlying earnings acceleration.
| Metric | Q2 2026 | Q2 2025 | Q1 2026 | Read-through |
|---|---|---|---|---|
| Revenue | $135.2M | $96.9M | $62.6M | Liftings and pricing drove the jump (Income Statement) |
| Diluted EPS | $0.39 | $0.08 | $(0.90) | Above published consensus of ~$0.05 (Income Statement) |
| Adjusted net income | $(0.3)M | $2.3M | $(47.2)M | Essentially breakeven after excluding derivative effects (Adjusted Net Income reconciliation) |
| Adjusted EBITDAX | $54.8M | $49.9M | $11.6M | Up 10% year over year (Adjusted EBITDAX reconciliation) |
| Free cash flow | — | — | — | $(15.1)M for the first half (Free Cash Flow reconciliation) |
| Net debt | $146.6M | — | $1.1M at Dec. 31, 2025 | Leverage rose sharply as the investment program accelerated (Net Debt reconciliation) |
The quality of the EPS beat is weak. The $42.4 million GAAP profit included an $18.7 million net derivative gain, including a $43.7 million unrealized gain; adjusted net income was instead a $0.3 million loss. That makes the reported EPS beat much less representative of recurring operating profitability.
Operations were better, but the improvement was partly timing-driven. NRI sales volumes rose 48% sequentially to 1.621 million BOE, and realized pricing increased to $80.77 per BOE from $57.21. However, the company says the volume surge was primarily tied to the timing of Gabon liftings, while production was only 10% above Q1 and 2% below the prior-year quarter. Q2 sales were above the midpoint of guidance, which supports execution but does not establish a durable run-rate. 〔0〕
The outlook was maintained rather than improved. Vaalco reaffirmed the elevated full-year 2026 production and sales ranges that had already been raised in May, while keeping the capital budget unchanged. Q3 guidance calls for NRI production of 17,200–18,900 BOEPD and sales of 17,200–18,900 BOEPD, with $75 million–$115 million of capital spending. 〔1〕
Cash generation and leverage remain the key offset. First-half operating cash flow of $34.5 million was overwhelmed by $156.2 million of investing cash use, leaving free cash flow negative $15.1 million after dividends. Debt increased to $177.0 million while cash fell to $30.4 million. The company did spend below the low end of Q2 capex guidance, but the balance sheet is carrying materially more financing risk than at year-end.
Net: a narrow earnings beat, not a clean fundamental re-rating. The filing delivers better-than-expected reported EPS, stronger sales execution and reaffirmed growth plans. But adjusted earnings were effectively flat, free cash flow was negative and the EPS upside was dominated by a non-cash hedging gain. That combination supports a narrow positive scorecard rather than a broad operating beat.
Read the original 8-K on SEC EDGAR ↗